Vertex Pharmaceuticals Incorporated
- Jurisdiction
United States - LEI
54930015RAQRRZ5ZGJ91 - ISIN
US92532F1003 (VRTX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Read full profile
Fundamentals
- Net revenue
€9.74B - Gross margin
86.1% - EBIT
€3.35B - EBIT margin
34.4% - Net income
€3.10B - Net margin
31.9%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Bhatia Sangeeta N. | N/A |
|
|
|
|
| Kewalramani Reshma | CEO & President |
|
|
|
|
| SACHS BRUCE I | N/A |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| David Taylor | September 2, 2025 | $1.00K–$15.00K |
| Lisa McClain | August 13, 2025 | $1.00K–$15.00K |
| Lisa McClain | August 13, 2025 | $1.00K–$15.00K |
| Jefferson Shreve | June 22, 2025 | $15.00K–$50.00K |
| Byron Donalds | April 14, 2025 | $1.00K–$15.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
| James Anderson |
|
|
|
Sell |
| John D. Spears |
|
|
|
Sell |